This trial will utilize genomic, proteomic, epigenomic, and metabolomic data to determine the different mechanisms underlying treatment efficacy and the development of resistance to afatinib of non-small cell lung cancer patients expressing EGFR. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.